Basic Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jul 15, 2024; 16(7): 3118-3157
Published online Jul 15, 2024. doi: 10.4251/wjgo.v16.i7.3118
Kombo knife combined with sorafenib in liver cancer treatment: Efficacy and safety under immune function influence
Yang Cao, Pei-Pei Li, Bing-Li Qiao, Quan-Wang Li
Yang Cao, Pei-Pei Li, Bing-Li Qiao, Department of Oncology, The Third People's Hospital of Zhengzhou, Zhengzhou 450000, Henan Province, China
Quan-Wang Li, Department of Oncology, The Affiliated Oriental Hospital of Beijing University of Chinese Medicine, Beijing 100078, China
Author contributions: Cao Y conceived and designed research; Li PP performed experiments; Qiao BL interpreted results of experiments; Li QW analyzed data; Cao Y prepared figures; Li PP drafted paper; Qiao BL and Li QW edited and revised manuscript; All authors read and approved final version of manuscript.
Supported by Henan Province Medical Science and Technology Tackling Program Joint Co-Construction Project, No. LHGJ20191024.
Institutional review board statement: This study obtained approval from the Ethics Committee of The Third People's Hospital of Zhengzhou, and every patient signed an informed consent form following the Helsinki Declaration.
Institutional animal care and use committee statement: Animal research was performed following the Regulations on the Administration of Experimental Animals in Medical Research and the ARRIVE Guidelines for animal management and studies, and approval was obtained from the Institutional Animal Ethics Committee of The Third People's Hospital of Zhengzhou.
Informed consent statement: Every patient signed an informed consent form following the Helsinki Declaration.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request at lpp20210224@hhu.edu.cn.
ARRIVE guidelines statement: The authors have read the ARRIVE Guidelines, and the manuscript was prepared and revised according to the ARRIVE Guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Pei-Pei Li, MM, Attending Doctor, Department of Oncology, The Third People's Hospital of Zhengzhou, No. 136 Nanshuncheng Street, Guancheng District, Zhengzhou 450000, Henan Province, China. lpp20210224@126.com
Received: September 27, 2023
Peer-review started: September 27, 2023
First decision: December 7, 2023
Revised: January 2, 2024
Accepted: March 20, 2024
Article in press: March 20, 2024
Published online: July 15, 2024
Processing time: 289 Days and 4.6 Hours
ARTICLE HIGHLIGHTS
Research background

This study explores an advanced approach to managing hepatocellular carcinoma (HCC), integrating data analytics from The Cancer Genome Atlas (TCGA) and innovative treatments, notably the Kombo Knife and sorafenib regimen. It emphasizes the need for holistic management strategies in HCC treatment, leveraging genomic insights.

Research motivation

The motivation behind this research is to address key challenges in HCC treatment by exploring the therapeutic potential of combined Kombo Knife and sorafenib regimen. The study aims to solve significant issues in HCC management by understanding the immunological genes and mechanisms through TCGA data analysis, contributing to future research advancements in this domain.

Research objectives

The primary objective is to identify immunological genes and the underlying mechanisms of the Kombo Knife and sorafenib regimen in HCC treatment. By using TCGA data and machine learning, the study seeks to enhance the understanding and effectiveness of HCC treatments, marking a significant stride in oncological research.

Research methods

The study employs a combination of weighted gene coexpression network analysis, machine learning, and RNA sequencing data from TCGA to evaluate immune attributes in postablation HCC. Additionally, it critically examines the therapeutic landscape and safety metrics of the combined treatment across cellular and animal models.

Research results

Significant findings include the identification of immune genes, specifically peptidylprolyl isomerase A and solute carrier family 29 member 3, as key prognostic markers. The combined treatment of Kombo Knife with sorafenib showed enhanced outcomes like prolonged progression-free survival and increased overall response rate in HCC.

Research conclusions

The study concludes that the innovative combination of Kombo Knife with sorafenib, rooted in immune-centric strategies, is a promising modality in HCC treatment. It underscores the effectiveness of integrating genomic data analysis with progressive therapeutic approaches.

Research perspectives

Future research should focus on further elucidating the immunological mechanisms behind the combined treatment, exploring its broader applicability, and refining the integration of genomic data for personalized HCC management. This direction promises to unlock new therapeutic frontiers in oncology.